Sprint Bioscience AB (publ)

OM:SPRINT Stock Report

Market Cap: SEK 54.9m

SPRINT Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Sprint Bioscience AB (publ) Competitors

Price History & Performance

Summary of share price highs, lows and changes for Sprint Bioscience
Historical stock prices
Current Share PriceSEK 0.52
52 Week HighSEK 2.25
52 Week LowSEK 0.36
Beta-0.56
1 Month Change15.56%
3 Month Change-19.00%
1 Year Change-60.90%
3 Year Change-82.07%
5 Year Change-94.02%
Change since IPO-96.75%

Recent News & Updates

Recent updates

Estimating The Fair Value Of Sprint Bioscience AB (publ) (STO:SPRINT)

Jun 12
Estimating The Fair Value Of Sprint Bioscience AB (publ) (STO:SPRINT)

A Look At The Intrinsic Value Of Sprint Bioscience AB (publ) (STO:SPRINT)

Feb 19
A Look At The Intrinsic Value Of Sprint Bioscience AB (publ) (STO:SPRINT)

Is Sprint Bioscience (STO:SPRINT) In A Good Position To Deliver On Growth Plans?

Nov 19
Is Sprint Bioscience (STO:SPRINT) In A Good Position To Deliver On Growth Plans?

Shareholder Returns

SPRINTSE BiotechsSE Market
7D6.3%2.3%1.8%
1Y-60.9%-5.1%-0.6%

Return vs Industry: SPRINT underperformed the Swedish Biotechs industry which returned -8.5% over the past year.

Return vs Market: SPRINT underperformed the Swedish Market which returned -1% over the past year.

Price Volatility

Is SPRINT's price volatile compared to industry and market?
SPRINT volatility
SPRINT Average Weekly Movement13.0%
Biotechs Industry Average Movement10.4%
Market Average Movement6.4%
10% most volatile stocks in SE Market14.0%
10% least volatile stocks in SE Market3.3%

Stable Share Price: SPRINT's share price has been volatile over the past 3 months compared to the Swedish market.

Volatility Over Time: SPRINT's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Swedish stocks.

About the Company

FoundedEmployeesCEOWebsite
200938Johan Emilssonwww.sprintbioscience.com

Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer.

Sprint Bioscience AB (publ) Fundamentals Summary

How do Sprint Bioscience's earnings and revenue compare to its market cap?
SPRINT fundamental statistics
Market capSEK 54.87m
Earnings (TTM)-SEK 20.85m
Revenue (TTM)SEK 62.38m
0.9x
P/S Ratio
-2.6x
P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SPRINT income statement (TTM)
RevenueSEK 62.38m
Cost of RevenueSEK 26.28m
Gross ProfitSEK 36.10m
Other ExpensesSEK 56.94m
Earnings-SEK 20.85m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-0.20
Gross Margin57.87%
Net Profit Margin-33.42%
Debt/Equity Ratio0%

How did SPRINT perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/10 14:58
End of Day Share Price 2025/07/10 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sprint Bioscience AB (publ) is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Siri LadowDanske Bank
Johan UnnerusRedeye